DJIA 16,027.05 -177.92 -1.10%
NASDAQ 4,283.75 -79.39 -1.82%
S&P 500 1,853.44 -26.61 -1.42%
market minute promo

Amgen (NASDAQ: AMGN)

143.00 -2.04 (-1.41%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AMGN $143.00 -1.41%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $143.50
Previous Close $145.04
Daily Range $140.16 - $144.57
52-Week Range $130.09 - $181.81
Market Cap $107.9B
P/E Ratio 13.97
Dividend (Yield) $4.00 (2.8%)
Ex-Dividend Date
Dividend Pay Date
02/11/16
03/08/16
Volume 4,626,825
Average Daily Volume 4,091,319
Current FY EPS $10.05

Sector

Healthcare

Industry

Drug Makers

Amgen (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/

News & Commentary

Biogen Inc. Takes Aim at Johnson & Johnson

Biogen's Samsung Bioepis has Remicade in its crosshairs.

Ligand Pharmaceuticals (LGND): Q4 Earnings Preview

Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Cat

Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

Pharmaceuticals Turn To Politics To Protect Prices

AbbVie Stands For Abnormally Vulnerable

Amgen's Blincyto and Repatha Positive in Phase III Studies

Leerink Is Back On Board The Biotech Train

Samsung Bioepis And Biogen: A Profitable Case For SB2 And Enbrel

Will 2016 Be Amgen Inc.'s Best Year Yet?

Amgen garnered a half-dozen drug approvals between December 2014 and the end of 2015, and the company delivered record full-year sales and profits in 2015. Could 2016 prove even better?

Gilead Reports Record Results, Street Remains Bored: Why? What's Next?

See More AMGN News...

AMGN's Top Competitors

AMGN $143.00 (-1.41%)
Current stock: AMGN
GILD $85.26 (0.14%)
Current stock: GILD
CELG $99.18 (1.32%)
Current stock: CELG
$0.00 (0.00%)
Current stock: